Adarx Pharmaceuticals ADRX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 85th percentile, 5-year average -18.4x
Near the top of its 5-year range · 98th percentile, 5-year average -6.0x
#3616 of 5330 stocks by PB (1 = cheapest)
Below its usual level · 25th percentile, 5-year average 265.3x
#5028 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.75 | – | -6.01 | 98% (pricier than usual) | #3616 of 5330 (1 = cheapest) |
| PE | -15.52 | -9.05 | -18.37 | 85% (pricier than usual) | – |
| PS | 257.70 | 513.93 | 265.31 | 25% (cheaper than usual) | #5028 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ADRX.
Sign in to join the discussion.